Research Watch
Therapies, AI models, biomarker tools, and other developments worth watching, with evidence levels kept in view.
This watch list follows the therapies and research tools attracting attention in the longevity field. Some are highly experimental. Some are moving toward stronger validation. All of them need to be viewed through the lens of evidence quality, not wishful thinking.
Cellular Reprogramming
Using transcription factors (Yamanaka factors) to partially or fully reset a cell's epigenetic age. Shows strong results in animal studies. Human safety data is very limited.
Senolytics
Drugs or compounds that selectively clear senescent cells that accumulate with aging and drive inflammation. Early human trials show safety and some biomarker effects.
Stem Cell Therapy
Deploying stem cells or cell-derived factors to regenerate damaged tissue or restore declining cell populations. Highly indication-specific -- some uses are clinically established, longevity applications are investigational.
Gene Therapy
Modifying gene expression related to longevity pathways such as telomere maintenance, DNA repair, or mTOR signaling. Some early human self-experiments; no established longevity protocols.
mTOR Inhibition (Rapamycin)
Repurposing the immunosuppressant rapamycin at low doses to inhibit the mTOR nutrient-sensing pathway. One of the most consistently replicated lifespan-extension results across animal species; human geroscience trials are underway but not yet conclusive.
NAD+ Precursor Supplementation
Supplementing with NAD+ precursors such as NMN or NR to counter the age-related decline in cellular NAD+ levels, which affects energy metabolism and DNA repair. Widely marketed as a supplement despite human trial results being inconsistent and considerably weaker than animal findings.
Parabiosis-Inspired Plasma Therapies
Interventions inspired by parabiosis research, where sharing blood circulation between young and old animals rejuvenated aged tissue, aiming to identify and administer the specific young-blood factors responsible. Human applications remain investigational, and regulators have warned against unproven clinics offering young-donor plasma infusions.